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Background: Mercury vapor poses a known health risk with no clearly established safe level of exposure.
Consequently there is debate over whether the level of prolonged exposure to mercury vapor from dental amalgam
fillings, combining approximately 50% mercury with other metals, is sufficiently high to represent a risk to health. The
objective of our study is to determine if mercury exposure from amalgam fillings is associated with risk of adverse
health effects.
Methods: In a large longitudinal non-blind sample of participants from a preventative health program in Calgary,
Canada we compared number of amalgam fillings, urine mercury measures and changes in 14 self-reported health
symptoms, proposed to be mercury dependent sub-clinical measures of mental and physical health. The likelihood of
change over one year in a sample of persons who had their fillings removed was compared to a sample of persons
who had not had their fillings removed. We use non-parametric statistical tests to determine if differences in urine
mercury were statistically significant between sample groups. Logistic regression models were used to estimate
the likelihood of observing symptom improvement or worsening in the sample groups.
Results: At baseline, individuals with dental amalgam fillings have double the measured urine mercury compared
to a control group of persons who have never had amalgam fillings. Removal of amalgam fillings decreases
measured urine mercury to levels in persons without amalgam fillings. Although urine mercury levels in our
sample are considered by Health Canada to be too low to pose health risks, removal of amalgam fillings reduced
the likelihood of self-reported symptom deterioration and increased the likelihood of symptom improvement in
comparison to people who retained their amalgam fillings.
Conclusions: Our findings suggest that mercury exposure from amalgam fillings adversely impact health and
therefore are a health risk. The use of safer alternative materials for dental fillings should be encouraged to avoid
the increased risk of health deterioration associated with unnecessary exposure to mercury.Background
Due to the potential health risks associated with expos-
ure to mercury, the use of dental amalgam fillings re-
mains a source of controversy. Exposure to mercury
vapor is a known health risk with no clearly established
safe level of exposure [1]. Dental amalgam fillings are a
major source of mercury exposure in the general popula-
tion, with several studies showing a correlation between
the number of amalgam surfaces and brain, blood and
urine concentrations of mercury [2-9]. The continued* Correspondence: zwicker1@ucalgary.ca
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have negative health consequences in the Canadian
population. As alternative restorative materials to amal-
gam exist, continued use of amalgam represents an un-
necessary exposure to toxicity risk from mercury. Health
Canada’s 1996 Position Statement on Dental Amalgam
assessed, however, that there was not sufficient evidence
to support a ban on the use of amalgam fillings or the
removal of sound amalgam fillings in patients who have
no indication of adverse health effects attributable to
mercury exposure [10].
Amalgam dental fillings have been an accepted part of
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to 50.5% mercury by weight with other metals typically
including silver (40 to 70%), tin (12 to 30%), copper (12
to 24%), indium (0 to 4%), palladium (0.5%) and zinc (0
to 1%) [13]. Mercury has an important role in amalgam
composition due to its unique property of being the only
metal that is in the liquid phase at room temperature [14].
The widespread use of amalgam fillings can be attributed
to their being easily prepared, relatively inexpensive and
highly durable [15]. Mercury vapor is continuously re-
leased from amalgam restorations, the rate of which de-
pends on the number of amalgam surfaces, location of
the amalgam surfaces, age, eating/chewing habits and
amalgam composition and condition [16,17]. Mercury
is a highly toxic metal, 80% of which is absorbed when
inhaled and carried by the blood to cells in all organs of
the body [18]. Typically mercury vapor is absorbed by
the body and oxidized to ionic mercury (mercuric form
Hg++), which can covalently bind with cell proteins
[19]. This means almost any protein can be damaged if
sufficient levels of mercury are present. Mercury is
cytotoxic, neurotoxic, immunotoxic, and nephrotoxic,
as occupational exposure to high doses of elemental
mercury has been shown to impact the immune, renal
and nervous system [20]. The central nervous system
(CNS) is a sensitive and critical target organ due to the
ability of elemental mercury to cross the blood brain
barrier and access the CNS [21]. Mercury has a high af-
finity for selenoproteins, which are important for de-
creasing oxidative stress [22]. The effects of mercury on
neural tissue are diverse at these levels of exposure and
can include mood changes, memory and concentration
problems, headache, fatigue, reduction in hand steadi-
ness, and manual dexterity [17,23-28].
While it is clear that mercury vapor is toxic, there is de-
bate over whether the level of exposure resulting from den-
tal amalgam fillings is sufficiently high to produce toxic
effects in the body. The World Health Organization states
“mercury may have no threshold below which some ad-
verse effects do not occur” [1]. Other groups like the
Human Biomonitoring Commission (HBM) of the German
Federal Environment Agency determined that published
scientific evidence and expert opinion demonstrates that
there “is no risk for adverse health effects and, conse-
quently, no need for action” for the level of mercury ex-
posure from dental amalgam below the HBM-I level
(5 μg/g-creatinine) [29]. The HBM-II level of 20 μg/g-
creatinine is suggested as a level for increased risk of
adverse health effects. Urine mercury levels from dental
amalgam fillings are typically under 3 μg/g-creatinine,
and toxicity symptoms from mercury exposure have
only been consistently shown in the range of 23 to
75 μg/g-creatinine in occupational settings, with some
additional evidence of toxicity symptoms in the rangeof 2.1 to 22 μg/g-creatinine for dental professionals
working with dental amalgam materials [20,30,31]. These
reference levels of exposure are reflective of acute,
short term exposure to mercury associated most often
with occupational exposure and may not be relevant for
assessing the prolonged, low dose exposure from dental
amalgam. Safety levels remain undefined for long-term,
low-dose mercury exposure. A study by Richardson
[32] translated the dose associated with amalgam ex-
posure to compare to the Canadian chronic reference
exposure level (REL) and found that the maximum
number of amalgam surfaces was 4.4 and 7.3 for fe-
males and males respectively, before exceeding the
Health Canada REL for Hg0 of 0.011 μg/kg-day. Given
the estimated 17 year half-life of mercury in the brain
[16,18,33-35], there is also concern that urine mercury
levels are not reflective of the mercury burden in the
CNS and some of the subsequent symptoms reported
from chronic exposure.
Given the controversy over the potential adverse
effects of prolonged exposure to low doses of mercury
vapor from amalgam fillings, our study looks at
whether the removal of amalgam fillings is associated
with health changes compared to a control group of
persons who did not have their fillings removed. We
interpret significant associations between amalgam
removal and symptom change as reflective of risks to
health associated with dental amalgam. Based on defini-
tions of reference levels for exposure like HBM, we
interpret the existence of increased risk at any level of
mercury as relevant to regulatory decision making in
health as opposed to demonstration of sufficient dam-
age to health. Dental amalgam fillings have unique
regulatory treatment in Canada because their use pre-
dates the enactment of safety regulation for medical
devices (which includes dental amalgam) [10]. Where
medical devices must be shown to be safe (absent of
harm or risk) before they can be approved for use, den-
tal amalgam can remain in use until there is evidence
of risk to health.
We use a longitudinal sample of participants in a
preventative health program in Calgary, Alberta. Mea-
sures from the sample include the number of amalgam
filling surfaces, urine mercury (μg/g-creatinine) and
self-reported health symptoms proposed to be both
mercury dependent and reflect sub-clinical measures
of mental and physical health [36]. In addition, a number
of participants chose to have their dental amalgams re-
moved allowing for comparisons over at least 6 months’
time between a group who never had amalgam fillings
(never amalgam group) with the samples of individuals
who had their amalgams removed (treatment group)
or those who did not have their amalgams removed
(positive group).
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Our data set provides information on participants in the
Pure North S’Energy Foundation program (henceforth
“Pure North”), which is a philanthropic wellness and
chronic-disease prevention program based in Calgary,
Alberta, Canada. Participants from the general public
self-selected into the Pure North program, which as-
sesses participant health status using questionnaires, bio-
metric measurements and laboratory tests to provide
personalized preventive health care services. Healthcare
workers at Pure North (including nurses, doctors, and
dentists) provide participants with lifestyle counselling,
dietary supplementation with vitamins, minerals and
other nutrients and dental care.
There are three identifiable groups in our analysis.
The first group is the “treatment group”, those individ-
uals who had their amalgam fillings completely re-
moved. To be included in our analysis for urine
mercury changes, participants who had their amalgam
fillings removed also had to have a post-removal mer-
cury measure at least six months after the fillings were
removed. The second group consists of individuals who
have a positive number of amalgam surfaces through-
out the study period and who have a second urine mer-
cury measure at least six months after their first
measure, referred to as “positive amalgam group”. The
third group is referred to as the “never amalgam group”
and is used to compare our study groups to the base-
line urine mercury level of a sample of Pure North par-
ticipants who have never had amalgam restorations.
Our ability to compare our study groups to persons in
the Pure North program who have never had amalgams
is limited to baseline mercury levels. Change in mer-
cury was not assessed in the never amalgam group be-
cause individuals with no amalgam fillings and normal
mercury levels were not retested in the Pure North pro-
gram, thus there were very few individuals who never had
amalgams with two mercury measures in the dataset.
There was no cost to the majority of participants in
our sample for the services offered, including dental
care. Our sample includes individuals in the Pure North
program between September 2010 and August 2013.
Participants enrolled after January 2013 with an income
over $25000 were required to pay a fee for the Pure
North program ranging from $600- 3000 depending on
the individual’s income. This involved 6 people in the
urine mercury measure group and 5 people in the self-
reported symptom group. All dental care was cost-
shared between dental insurance and Pure North, with
no cost to the individual. Program delivery was the
same for all participants.
The data gathering process employed by Pure North
with respect to urine mercury and amalgam surfaces
has been described in detail elsewhere [37]. Briefly,participants in the Pure North program self-selected
into the program and had routine biomarker measure-
ments and provide survey reports on their wellness as
part of their personalized health program. All partici-
pants in the study received lifestyle counseling and
bio-detoxification supplements including: N-Acetyl-
Cysteine (NAC), Alpha-Lipoic Acid (ALA) and a high
potency multivitamin mineral supplement. Health care
workers administered all tests. As part of the health
assessment all Pure North participants had the num-
ber of dental amalgam surfaces assessed and all partic-
ipants were offered the option to test their urine
mercury levels. All participants with amalgam fillings
were offered the opportunity to have their amalgam
fillings removed by a dedicated dental team at a state-
of-the art facility for the safe removal of mercury
amalgam fillings and dental restoration, with extensive
precaution to minimize exposure to mercury vapor
and amalgam particles. Dental benefits and risks were
discussed during the initial consultation. Informed
consent was obtained prior to amalgam removal. Par-
ticipation in the Pure North program was not contin-
gent on amalgam removal.
There are two parts to our analysis. First, we compare
urine mercury levels in the treatment and positive dental
amalgam groups at baseline and after at least 6 months
post amalgam removal, or after starting the Pure North
program. We also compared urine mercury level of these
groups to the baseline urine mercury level of a sample
of participants who never had amalgam fillings. Second,
we compare changes in 14 self-reported symptoms after
at least one year for those in the treatment and positive
amalgam groups to assess if health symptoms are more
likely to improve, and not worsen, after amalgam removal.
The symptoms are sub-clinical measures of mental and
physical health that have been proposed as mercury
dependent. We interpret the odds ratios as reflective of
risks to health associated with dental amalgam. Based
on definitions of reference levels for exposure like
HBM, we interpret the existence of increased risk at
any level of mercury as relevant to regulatory decision
making in health.
Data collection
A dentist recorded each individual’s number of amal-
gam surfaces after visual inspection and x-rays. Age,
sex, weight, and symptom severity were gathered from
routinely administered surveys and medical professional
consultations. Mercury levels were measured from a sam-
ple provided by consenting participants at an appoint-
ment. The urine samples were sent by priority shipping to
Doctor’s Data, Inc. (St. Charles, IL). On receipt, aliquots
of each creatinine sample were made and the remaining
sample was acidified to preserve mercury. Creatinine
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method on a Beckman Coulter AU680. Samples were pre-
pared for elemental testing based on creatinine level and
measured using ICP-MS (Perkin Elmer DRCII) [38]. Urine
mercury concentrations are reported as μg/g-creatinine to
reduce error introduced by variation in sample volume.
Urine samples were used as they are a valid measure of
body burden from long term constant exposure to elem-
ental mercury [39].
Variables & statistical analysis
We use the number of amalgam surfaces rather than a
count of amalgam fillings because there can be several
amalgam surfaces per filled tooth releasing mercury
vapor (typical molars have five surfaces, and on average,
there are 2 amalgam surfaces per filled tooth) [32]. Some
of the observations on total amalgam surfaces differed
between baseline and at one year in the program. Indi-
viduals in the positive amalgams group, with differences
in number of amalgams surfaces greater than 5, were ex-
cluded from the study sample. Individuals whose total
surfaces did not change by more than 5 were retained as
members of the positive amalgams group. It is possible
that those individuals with total surface changes smaller
than 5 had a constant and positive number of amalgams,
but the recorded values are measured with error because
of differences between those inspecting the amalgams,
the way the amalgams were inspected (x-ray versus by
sight), or possible transcription errors (that would be
present in any administrative data set).
To be included in the analysis of a sample of self-
reported symptoms that could indicate mental or phys-
ical health changes related to exposure to mercury,
individuals did not need to provide a mercury measure.
All variables for the symptom analysis were reported on
a scale of 1 to 10, with 10 representing often experien-
cing the symptom and 1 representing never experien-
cing the symptom. Respondents are instructed that
“your responses indicate how you feel today”. The 14
symptoms reported are: headaches or migraines; memory
loss; depression; fatigue or sleep disturbance; anxiety;
being unusually moody; confusion; stomach problems;
experiencing loss of sense of smell or taste; shakiness in
hands; parasthesia; unintentionally dropping things;
coordination problems and muscle weakness.
For the comparison of urine mercury levels we con-
ducted a non-parametric Kruskal-Wallis equality-of-
populations rank test with Dunn’s multiple comparison
post hoc test and Bonferroni correction to compare the
distributions of our sample across groups. We present
box plots to show the distribution of mercury in the
groups. A Wilcoxon signed-rank test was used for inter-
group comparison or comparison of two related measures
in the treatment and positive amalgam groups. Self-reported symptoms are reported using an ordinal scale,
where we consider within-individual changes in symptom
score to indicate improvement (or worsening) versus a
lack of improvement (or worsening) in the symptom. We
define decreases in symptom scores at least one year from
baseline as symptom improvements and increases in
scores at least one year from baseline as symptom worsen-
ing. The positive amalgam group symptom change com-
pared the reported symptom scores at least one year after
the first symptom score report and the treatment group
compares the symptom scores at entry to the Pure North
program and at least one year following amalgam removal.
We then estimate the odds of observing symptom im-
provement (or worsening) in the treatment group and the
positive amalgam group using logistic regression models.
Odds ratios are reported with respect to having amalgams
removed, controlling for age and sex.
The variables used in this analysis were summarized
with means and standard deviations (SD) for continuous
variables and percentages for binary or categorical vari-
ables. Unless otherwise stated, for tests of significance,
we used a significance level of p ≤ 0.05 to determine evi-
dence of an association. All analyses were conducted in
Stata 13. Ethics approval for this study was obtained
from the University of Calgary (Ethics ID E-24890).
Results
Characterization of the age, sex and urine mercury levels
of the treatment, positive amalgam and never amalgam
groups are shown in Table 1. Females were more repre-
sented in the positive amalgam and treatment groups
with 60% and 57% females respectively. The never amal-
gam group was 33% female. The never amalgams group
was younger (mean age 46.7 years) than the treatment
group or the positive amalgam group (53.7 and 54.3 years).
The positive amalgam group had a higher mean num-
ber of amalgam surfaces (23.7 surfaces) than the treat-
ment group (18.4 surfaces) (Wilcoxon signed-rank test,
p <0.05).
Boxplots demonstrate the distribution of urine mer-
cury for the study groups with a clear right skew
(Figure 1) which has been deemed important for studying
mercury exposure from dental amalgam [40]. The arith-
metic mean for urine mercury concentration at baseline
for the never amalgam group was 0.78 μg/g-creatinine.
The mean urine mercury level of participants with one
or more amalgam surfaces is about double that observed
for the participants with 0 dental amalgam surfaces
(1.61 μg/g-creatinine and 0.78 μg/g-creatinine respectively
(Wilcoxon signed-rank test, p <0.001, Table 1 and Figure 1).
Positive amalgam and treatment group baselines were not
significantly different. The urine mercury level in females
was consistently higher than the level in males for all
groups (Kruskal-Wallis test, p <0.001, Table 2). Higher
Table 1 Summary data for study sample with urine mercury measures
Treatment group (N=250) Positive Amalgam group (N=167) Never Amalgam group (N=538)
% Female 57% 60% 33%
Age 53.7 (9.5) 54.3 (9.0) 46.7 (14.3)
Baseline Hg Overall 1.61 (1.27) 1.67 (1.64) 0.78 (1.43)
Baseline Hg Males Only 1.18 (0.97) [107] 1.42 (1.72) [67] 0.54 (0.77) [358]
Baseline Hg Females Only 1.92 (1.37) [143] 1.85 (1.56) [100] 1.24 (2.14) [180]
% above HBM-1 (proportion) 3.2% (8/250) 3.0% (5/167) 0.9% (5/538)
Number of Amalgam Surfaces at Baseline 18.4 (12.9) 23.7 (13.8) 0 N/A
Baseline values of average urine mercury measures (μg/g-creatinine) overall, for males and females across all amalgam groups. Percent above the established
HBM-I risk level of 5 μg/g-creatinine overall for each group. Arithmetic mean (standard deviation) [number of observations], unless otherwise specified.
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line urine levels of mercury in the positive and treat-
ment group (Figure 2). The averages in the treatment
group ranged from 1.03 μg/g-creatinine for 1–5 surfaces
to 2.10 μg/g creatinine for 26+ surfaces (Figure 2). A
Wilcoxon signed-rank test was used for inter-group
comparison between baseline and follow-up, and all
were statistically significant except those indicated by a
lower case letter (p < 0.05, Figure 2).
The average urine mercury levels are low enough to be
considered safe and posing no risk of adverse health effects
according to the HBM values for mercury. The HBM I
value (5 μg/g-creatinine) represents the concentration of a












Figure 1 Comparison of the baseline and follow-up urine mercury me
whisker plots showing distributions of urine mercury concentrations for each
Table 3. Boxes extend from the 25th to the 75th percentile, horizontal bars in
minimum observations within 1.5 times the length of the interquartile range
are represented as circles. Group comparison was performed using the Kruska
signed-rank test was used for inter-group comparison and all were statistically
not significantly different. Values >10 μg/g-creatinine have been removed for
positive group and two at 11 and 23 μg/g-creatinine in the never amalgam gaccording to the knowledge and judgment of the commis-
sion and with regard to the substance under consideration –
there is no risk for adverse health effects and, consequently,
no need for action. The HBM II value (20 μg/g-creatinine)
represents the concentration of a substance in human bio-
logical material above which there is an increased risk for
adverse health effects and, consequently, an urgent need
to reduce exposure and to provide individual biomedical
care (advice) [29]. In our sample 3.2% of the treatment
group, 3.0% of the positive amalgams group and 0.9% of
the never amalgam group had urine mercury levels exceed
the HBM-I level of safety (5 μg/g-creatinine). There was
only one individual in the never amalgams group who






asures for treatment and positive amalgam groups. Box and
group (μg/g-creatinine). Corresponding numeric data are provided in
side the boxes represent the median, whiskers extend to maximum and
above and below the 75th and 25th percentiles, respectively, and outliers
l-Wallis with Dunn’s multiple-comparison test p < 0.05. A Wilcoxon
significant (p < 0.001). Lower case letters indicates distributions that are
readability. * signifies an extreme outlier: one at 12 μg/g-creatinine in the
roup.
Table 2 Mean urine mercury measures for treatment group and positive amalgam group
Group Treatment group Positive amalgam group
(N=250) (N=167)
(M: 107, F: 143) (M: 100, F: 67)
Overall Baseline Mercury 1.61 (1.27) 1.67 (1.64)
Second Mercury 0.73 (0.75) 0.92 (0.90)
Males Only Baseline Mercury 1.18 (0.97) 1.42 (1.72)
Second Mercury 0.48 (0.48) 0.71 (0.66)
Females Only Baseline Mercury 1.92 (1.37) 1.85 (1.56)
Second Mercury 0.92 (0.86) 1.06 (1.01)
Mean urine mercury measures (μg/g-creatinine) for treatment group and positive amalgam group members with a second mercury measure at least six months
later. Mean (standard deviation) [number of observations]. The baseline mercury measure is the first measure available for the individual (pre-removal in the
treatment group). The second mercury measure is the last available mercury measure, post-removal in the treatment group.
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mercury levels at measurement at least six months later
(Table 2). Post-removal levels of mercury in the treat-
ment group were lower than the baseline levels overall
(Wilcoxon signed-rank test, p < 0.05, Figure 1) and
when broken out by number of surfaces (Wilcoxon
signed-rank test, p < 0.00, Figure 2). Post-removal levels
of mercury were not significantly different from the
never amalgams group at baseline (Figure 1). As part of
the Pure North program all of the individuals in our
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Figure 2 Comparison of baseline and follow-up urine mercury concen
whisker plots showing distributions of urine mercury concentrations for the
Boxes extend from the 25th to the 75th percentile, horizontal bars inside th
minimum observations within 1.5 times the length of the interquartile rang
outliers are represented as circles. A wilcoxon signed-rank test was used fo
those indicated by a lower case letter (p < 0.05). Values >10 μg/g-creatinine
at 12 μg/g-creatinine.supplement used for bio-detoxification, including NAC
and ALA. Consequently, the positive amalgams group
also had a reduction in urine mercury after at least six
months in the program that was 85% of the reduction
in the treatment group (−0.75 μg/g-creatinine compared to
−0.88 μg/g-creatinine) but the difference between groups
is not statistically significant (Table 2).
For each of the 14 self-reported symptoms potentially
influenced by mercury exposure, we estimate logistic
regression models of the odds of observing symptom
improvement and symptom worsening, distinguishingurfaces 11 to 15 surfaces
surfaces 26+ surfaces
Follow-up Treatment Group
Follow-up Positive Amalgam Group
b b c c
*
trations grouped by number of surfaces at baseline. Box and
treatment group and the positive amalgam group (μg/g-creatinine).
e boxes represent the median, whiskers extend to maximum and
e above and below the 75th and 25th percentiles, respectively, and
r inter-group comparison and all were statistically significant except
have been removed for readability. * signifies an extreme outlier
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removed and those that did not. The mean baseline self-
reported symptom scores were not significantly different
between the positive amalgam and treatment groups, ad-
justed for sex and age (Additional file 1). Odds ratios rep-
resent the increased or decreased likelihood of a symptom
change occurring in the treatment group when compared
to the positive amalgam group. For all 14 symptoms, the
odds ratios for symptom improvement for the treatment
group demonstrate greater odds of symptom improve-
ment in comparison with the positive amalgam group
(Table 3). Two of these odds ratios are significant with
p ≤ 0.05 (memory loss and stomach problems) and with
p ≤ 0.1 an additional 4 symptoms were significant (fatigue/
sleep disturbance, confusion, loss of sense of smell or
taste, shakiness in hands). Removal of fillings reduced
the odds that symptoms would worsen for all 14 symp-
toms. Odds ratios for five symptoms (confusion, stom-
ach problems, loss of sense of smell or taste, shakiness
in hands, coordination problems) were statistically signifi-
cant when p ≤ 0.05 and another two (headache, muscle
weakness) when p ≤ 0.1.
Discussion
In this study individuals with dental amalgam fillings
were found to have double the measured urine mercury
when compared to individuals with no dental amalgam
fillings. The combination of amalgam filling removal and
bio-detoxification was found to reduce urine mercury
levels equivalent to the never amalgam group. Our re-
sults agree with other studies that have shown that evenTable 3 One year odds of symptom improvement and worsen
Symptom Tx Group Symptoms Impro
Headache 1.222 {0.342}
Memory loss 1.600* {0.0255}
Depession 1.206 {0.370}
Fatigue/Sleep disturbance 1.499^ {0.0598}
Anxiety 1.143 {0.522}
Unusually Moody 1.368 {0.134}
Confusion 1.462^ {0.0832}
Stomach problems 1.571* {0.0360}
Loss sense of smell or taste 1.588^ {0.0727}
Shakiness in hands 1.499^ {0.0937}
Parasthesia 1.048 {0.849}
Unintentionally dropping things 1.173 {0.481}
Coordination problems 1.122 {0.628}
Muscle weakness 1.282 {0.246}
One year odds of symptom improvement and worsening in the treatment group co
treatment group relative to the positive amalgam group. {P values}; *indicates coeff
size 0.10.though amalgam removal initially produces a rise in
mercury levels, there is a significant reduction in urine
mercury to 60-76% of the initial levels six months later
[41-46].
We found similar reductions in urine mercury in the
treatment and positive amalgam groups. Our results
suggest that bio-detoxification reduces urine mercury
levels at 85% of the reduction of combination therapy
(bio-detoxification and amalgam removal). While there
was a greater reduction in the treatment group versus the
positive amalgam group, there was not a statistically sig-
nificant difference between these groups. The near
equivalence of bio-detoxification and amalgam removal
for reducing urine mercury has been demonstrated in
the literature [47].
It is notable that while amalgam fillings do increase
exposure to mercury, our samples show levels of urine
mercury considered to be safe according to current ref-
erence levels. Being below the HBM I reference level,
the exposure to mercury from dental fillings would be
considered to pose no risk to health and warrant no
action to address. As filling removal reduces mercury
levels which are already considered safe, there is also
the implication that removal of fillings would result in
no health benefit and if anything expose individuals to
the risk of bolus exposure to mercury at the time of
removal.
Our analysis of symptom change following amalgam
removal challenges the preceding assessments of the
safety of dental amalgam. In samples of persons with
mercury exposure below the HBM I threshold, we founding in the treatment group
Greater than one year















ntrolling for age and sex. Odds ratio coefficients are the odds of change in
icient is different from 1 at size 0.05; ^represents statistical significance at
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of reporting symptom improvement and decreased like-
lihood of self-reported symptoms worsening in compari-
son with those who retained their fillings. Significant
improvement attributable to the amalgam removal treat-
ment was seen for memory loss and stomach problems.
Significantly less deterioration was seen for confusion,
stomach problems, loss of sense of smell or taste, shaki-
ness in hands, and coordination problems.
Our results add to the body of evidence that there is
reduced likelihood of health complaints after removal
of the amalgam fillings, consisting of either a decrease
of subjective symptom burden overall or subtle effects
on symptoms, mood, motor function (hand steadiness)
and cognition [42,45-50]. Our findings suggest that there
remains increased risk of health deterioration in study
participants even with mercury levels below the estab-
lished HBM-I no risk urine mercury value. Subclinical ad-
verse neurobehavioral and psychological effects have been
associated with a dose–response relationship with urine
mercury levels that can occur with amalgam fillings (less
than 4 μg/g-creatinine) [17,26,51-55]. The possible dose–
response relationship between low-level mercury vapor
exposure and subclinical neurological and psychological
effects has been characterized previously as preclinical
symptoms (predominantly in dentists and dental assis-
tants) [17,51,56]. Symptom changes associated with amal-
gam removal have been seen in other studies and include
a diverse range of adverse effects including decreased
motor functioning (e.g., losses in hand steadiness and
manual dexterity, progressing to incoordination, imbal-
ance and tremor in muscles that perform fine motor
control) and loss of mental capacity (e.g., memory, con-
fusion, diminished logical reasoning and concentration)
[42,45,47,50]. Most of these studies are limited by their
small sample size (amalgam removal group sample sizes
of 20, 20, 60 and 796 respectively with the latter being
a retrospective study). There have been reports of an
absence of symptom improvement with amalgam re-
moval [46,48] however, the findings from these studies
are limited by treatment groups of 55 and 78 partici-
pants respectively, while our treatment group has 250
participants. It should be noted that the lack of signifi-
cant neurobehavioral or motor deficits associated with
low level mercury exposure seen in two randomized
control trials in children [57,58], do not address the ef-
fects that early toxic exposure to mercury may have on
health later in life [59].
The positive influence of amalgam removal on self-
reported symptom changes, suggests that bio-detoxification
is not equivalent to filling removal for health outcomes
despite reducing urine mercury levels (Figure 1). Bio-
detoxification and chelation therapies have been pro-
posed as potential treatments for health conditionsassociated with dental amalgams [47,50]. Bio-detoxification
may have affected mercury excretion so that urine mercury
is not an accurate measure of the mercury present and ac-
cumulated in the body. Typically urine is a good measure
of mercury from amalgams, as urine is not a primary
excretion route for methyl mercury and urine measures
reflect cumulative exposure over 2 to 4 months [60].
However, the percentage of total daily mercury excre-
tion by the urine route can range from 10% to 40%, de-
pending on the amalgam filling exposure, and it is
unclear how bio-detoxification affects this [61].
It is important to note that we are observing health
impacts of amalgam fillings in persons who would not
be expected to be at risk of health problems from
amalgam fillings. High levels of mercury in the diet, an
allergy to mercury, impaired kidney function and en-
vironmental or workplace exposure to mercury are all
contraindications for dental amalgams according to
Health Canada [62,63]. We have observed symptom
changes in persons without urine mercury levels asso-
ciated with dietary, environmental or occupational ex-
posures considered to be harmful. The improvements
we see are likely unrelated to allergy/hypersensitivity
where symptoms are clear and as a consequence those
members of the population would only be included in
our study in the never amalgam group.
Ultimately, there is concern that long-term exposure
to low levels of mercury can contribute to neurodegen-
erative disorders such as Alzheimer’s disease [64]. The
CNS is a sensitive target organ for mercury vapor ex-
posure, with the most consistent and pronounced effects
[21,65], although little is known about the distribution
pattern in the human brain. It is estimated that adults are
typically exposed to mercury from amalgam fillings at ap-
proximately 2 to 5 μg/ day and mercury has a significantly
longer half-life (over 17 years) in the brain [16,18,33-35].
Autopsy studies have shown that elevated brain mercury
levels are correlated with number of amalgam fillings and
individuals with more than 12 amalgam fillings have more
than 10-times higher mercury levels in several tissues in-
cluding the brain, compared to individuals with only 0–3
amalgam fillings [66,67]. However there have been no
clear clinically defined deficiencies with these levels of
mercury exposure. Given this information, the subclinical
symptoms experienced may be a reflection of the low level
continual dosing occurring from amalgam fillings. Our re-
sults suggest that removal of the fillings may stop this dos-
ing from occurring, but ultimately long term follow-up
studies are needed to investigate this. In the meantime,
given that mercury is highly neurotoxic and there is no
established benefit at any level of mercury, removing
amalgam fillings to prevent future buildup of mercury in
the brain may be important to reduce the risk of health
deterioration.
Zwicker et al. Environmental Health 2014, 13:95 Page 9 of 11
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removal of dental fillings was based on the initiative of the
patients resulting in a non-random selection of partici-
pants in the treatment group. Individuals in the treatment
group may report improvement based on more optimistic
expectations or gratitude in relation to having received the
intervention. Blinding was not possible in this study, as re-
placement of amalgam fillings was not masked. There is
evidence that the placebo effect from sham surgery can
last for over 12 months post-surgery [68,69]. Participants
in the treatment group may have had their concern allevi-
ated regarding possible adverse symptoms associated with
amalgam fillings (nocebo effect) [70]. We suggest that this
bias is unlikely to impact the urine mercury measures and
is isolated to the self-reported symptoms reporting. While
we cannot rule out this bias, we suggest that it is unlikely
as this bias would require a significant proportion of the
treatment and positive amalgam group to improve or not
improve respectively their answers to the questions a year
later. The self-reported symptom questions were embed-
ded as a part of an extensive health and wellness question-
naire and were not asked in the context of amalgam
removal. If this bias is present, the positive amalgam
group would also have increased odds of symptom im-
provement and decreased odds of symptom worsening,
based on their belief that the Pure North diet, lifestyle and
bio-detoxification counselling helped them.
Our findings are limited by what some will consider a
short time of observation, reliance on subjective, self-
reported health symptoms and lack of a control popula-
tion for comparison of changes over time. It is possible
that a longer follow-up period would provide different
symptom effects. A recent study characterized a reduction
of health complaints in persons 3 years after replacement
of dental amalgams in comparison to complaints from the
general population [45]. This emphasizes the magnitude
of health complaints attributed to dental amalgams that
can be reduced simply by removal of amalgam fillings.
However, the lack of direct correlation of symptom im-
provement with mercury measures is a limitation of this
and other studies [42]. Further, controversy exists with
other studies that have failed to find a positive correlation
between amalgam fillings and adverse self-reported symp-
toms [71-73]. This can be due at least in part, to the het-
erogeneity of patients with health complaints attributed to
amalgam fillings, with complaints ranging from local
intra-oral complaints to multiple general systemic com-
plaints. There is a spectrum of sensitivity to mercury such
that those most sensitive to mercury exposure receive
greater benefit from amalgam filling removal [74].
Conclusions
Mercury vapor poses a known health risk with no clearly
established safe level of exposure [1]. Amalgam dentalfillings are one of the largest sources of exposure to
mercury in the general population. Our study shows in-
dividuals with dental amalgam fillings have double the
measured urine mercury compared to a control group
of persons who have never had amalgam fillings. Re-
moval of amalgam fillings in persons with urine mer-
cury levels, considered by Health Canada to be too low
for adverse health effects, decreases measured urine
mercury to levels in persons without amalgam fillings
and reduces the odds of deterioration in self-reported
health symptoms compared to a sample of persons who
did not have their fillings removed within the one year
timeframe. The likelihood of symptom improvement in
comparison to people who retained their amalgam fill-
ings was also increased. Health Canada’s position state-
ment on amalgam removal indicated that there was not
sufficient evidence of adverse health effects due to mer-
cury exposure to support a total ban of amalgam or re-
moval of amalgams from patients. Ultimately our findings
suggest that mercury could have toxic effects at low levels
of exposure. The use of safer alternative materials for den-
tal fillings should be encouraged to prevent an unneces-
sary risk of health deterioration associated with mercury
exposure from dental fillings.
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